LifeSci Capital Rates Immix Biopharma (IMMX) buy
LifeSci Capital maintains its buy rating on IMMX, setting a target price of $19, a 117.39% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
LifeSci Capital rated Immix Biopharma, Inc. ($IMMX) "buy" with a $19 price target on June 17, 2026.
Since the rating, $IMMX is up 10.0% after 1 week, up 12.3% after 1 month and down 12.6% to date (from the $9.13 close on Jun 17, 2026).
IMMX
Immix Biopharma, Inc.
Key Points
- LifeSci Capital reiterated its buy rating on IMMX, maintaining a target price of $19 as of June 17, 2026.
- LifeSci Capital's $19 price target implies 117.39% upside from Immix Biopharma, Inc.'s ($IMMX) current $8.74 share price.
- IMMX shares are trading at $8.74, with strong institutional interest seen from firms like Janus Henderson and Saturn V Capital.
- Insiders including Helen Adams and Jane Buchan bought shares on May 22, 2026, reflecting ongoing confidence in IMMX.
Get $IMMX trade alerts by text
We text you when insiders, Congress or big funds trade $IMMX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Immix Biopharma, Inc. alert may contain errors. Disclosures
LifeSci Capital has reiterated its buy rating on IMMX, with a target price set at $19. This reaffirmation came on June 17, 2026, with IMMX shares currently trading at $8.74.
Other Institutional Activity in IMMX
Janus Henderson Group PLC increased its holdings in IMMX by 880,434 shares, ending with 4,802,002 shares valued at about $43.7 million. Saturn V Capital Management LP also expanded its stake by adding 694,416 shares, bringing its total to 3,693,585 shares worth approximately $33.6 million. Eventide Asset Management, LLC held steady, maintaining its position at 2,549,019 shares, valued at $23.2 million. Meanwhile, Vanguard Capital Management LLC made a significant move, acquiring 1,787,994 shares, and Millennium Management LLC added 90,422 shares, totaling 1,750,200 shares valued at $15.9 million. Marshall Wace, LLP, however, reduced its holdings by 337,191 shares, now holding 1,641,552 shares worth about $14.9 million.
Immix Biopharma, Inc. Stock Down 30.1%
IMMX shares are currently trading at $8.74. The stock has seen considerable interest from institutional investors, suggesting a positive outlook. While specific market cap and P/E ratio data are unavailable, the stock's current price indicates potential growth, especially given the recent analyst ratings.
$IMMX price target
Immix Biopharma, Inc. daily closes and this analyst's $19 target. Not advice.
Insider Buying and Selling at Immix Biopharma, Inc.
On May 22, 2026, several insiders made purchases of IMMX shares. Helen Adams acquired 12,500 shares, while Jane Buchan also purchased 12,500 shares. Magda Marquet and Jason Hsu each bought 6,250 shares, and Yekaterina Chudnovsky added 12,500 shares to her holdings. These transactions were not part of a pre-planned trading schedule, indicating personal confidence in the company's prospects.
Analysts Set New Price Targets
On June 17, 2026, LifeSci Capital reiterated its buy rating for IMMX with a $19 price target. Previously, HC Wainwright & Co. maintained its buy rating with a target of $20 on May 22, 2026. Mizuho also maintained its buy rating with a $15 target on March 30, 2026. The consensus among analysts remains positive, with a strong buy outlook and an average target price reflecting potential upside.
Bottom Line
IMMX has caught the attention of both institutional investors and insiders, with recent purchases highlighting confidence in its future. The reiterated buy rating from LifeSci Capital and positive analyst consensus suggest a favorable outlook for the company. Investors often track these developments as they provide insights into market sentiment and potential growth opportunities.
Related Filing Alerts
Source: LifeSci Capital's rating change on $IMMX (Jun 17, 2026). Written by software, not financial advice. How we make alerts